Population
Mouse neuroblastoma cell line and in vivo ACE2 knockout (ACE2) mice and non-transgenic littermates
Comparison
ACE2 gene therapy targeted to the… vs Non-transgenic littermates and untreated…
Design
Preclinical
Follow-up
10 days
Authors
Loading...
Supports PVN-targeted ACE2 therapy for cardiac dysautonomia; hypothesis-generating in mice and untested in humans.
ACE2 gene therapy targeted to the brain reduces oxidative stress and improves autonomic function, suggesting a potential therapeutic target for hypertension-associated dysautonomia.
Xia et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: